Ginkgo biloba  is  one of a well-known medicinal plant worldwide, where is prescribed in working on various diseases, such as diabetes mellitus type I and II, peripheral vascular abnormalities, and neurodegenerative illnesses like Alzheimer's disease . The purpose of this study was to know how oral Ginkgo biloba administration affected the liver, kidneys, hematological parameters, lipid profile, and hepatic gene expression in type I diabetic rats. Seventy-five male adult Sprague Dawely rats were allocated into five equal groups 15 rats each, 1^st group; control group, 2^nd group; diabetic group, 3^rd group; Ginkgo biloba group, 4^th group; Diabetic treated group received single oral dose of Ginkgo biloba after diabetic induction as a treatment and 5^th group; rats were administered daily single oral dose of Ginkgo biloba as a protective dose from the 1^st day of the study prior to diabetes induction and continued after the diabetes induction till the end of the work. The results of study revealed that   Ginkgo biloba actions in modulating of hepatic key genes GLUT-2 (glucose transporter-2), PPAR-α (Peroxisome proliferator-activated receptor alpha),and PGC1-α (The peroxisome proliferator-activated receptor gamma coactivator-1).Also, Ginkgo biloba possesses antihyperlipidemic activities, supports liver and kidney functions and improves glucose metabolism, storage and utilization in liver by enhancing its key genes. based on the outcomes of current study  Ginkgo biloba  is an effective food supplement or a supportive treatment for type I diabetes mellitus..